LlLLY/BOEHRINGER MANNHEIM DIABETES CO-PROMOTION ALLIANCE
LlLLY/BOEHRINGER MANNHEIM DIABETES CO-PROMOTION ALLIANCE agreement in principle will focus in the U.S. on co-promotion of B-M's Accu-Chek blood glucose monitoring devices and Lilly's Humulin insulin products, which are estimated to be a $600 mil. to $620 mil. sales franchise. Sales forces are currently being trained on both products with the goal of integrating insulin and glucose monitoring therapies, B-M reported. Lilly said sales reps are already co-promoting the products in the field.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth